Screening TRPV1 antagonists for the treatment of pain: lessons learned over a decade
暂无分享,去创建一个
P. Blumberg | A. Szallasi | József Lázár | Laxmikant Gharat | Neelima Khairathkar-Joshi | Peter M Blumberg | Arpad Szallasi | L. Gharat | J. Lazar | Neelima Khairathkar-Joshi
[1] A. Szallasi,et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept , 2007, Nature Reviews Drug Discovery.
[2] Vladimir A. Pavlyukovets,et al. Kinetics of Penetration Influence the Apparent Potency of Vanilloids on TRPV1 , 2006, Molecular Pharmacology.
[3] P. Blumberg,et al. Vanilloid (Capsaicin) receptors and mechanisms. , 1999, Pharmacological reviews.
[4] A. Moriondo,et al. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide , 2001, The Journal of physiology.
[5] M. Jarvis,et al. Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats. , 2006, Journal of neurophysiology.
[6] Uhtaek Oh,et al. Hot channels in airways: pharmacology of the vanilloid receptor. , 2002, Current opinion in pharmacology.
[7] S. Ito,et al. Novel Gating and Sensitizing Mechanism of Capsaicin Receptor (TRPV1) , 2008, Journal of Biological Chemistry.
[8] Ellen A. Lumpkin,et al. Spider toxins activate the capsaicin receptor to produce inflammatory pain , 2006, Nature.
[9] P. Várnai,et al. Dual Regulation of TRPV1 by Phosphoinositides , 2007, The Journal of Neuroscience.
[10] N. Carruthers,et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. , 2005, Journal of medicinal chemistry.
[11] S. Bevan,et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1) , 2001, British journal of pharmacology.
[12] A. Stein,et al. The Phosphoinositide 3-Kinase Binds to TRPV1 and Mediates NGF-stimulated TRPV1 Traffi cking to the Plasma Membrane , 2006 .
[13] J. Treanor,et al. Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1 , 2005, Molecular Pharmacology.
[14] J. Hell,et al. Protein Kinase A Anchoring via AKAP150 Is Essential for TRPV1 Modulation by Forskolin and Prostaglandin E2 in Mouse Sensory Neurons , 2008, The Journal of Neuroscience.
[15] L. Premkumar,et al. Induction of vanilloid receptor channel activity by protein kinase C , 2000, Nature.
[16] Mark H. Norman,et al. AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.
[17] P. Wyman,et al. Discovery of small molecule antagonists of TRPV1. , 2004, Bioorganic & medicinal chemistry letters.
[18] D. Mohapatra,et al. Regulation of Ca2+-dependent Desensitization in the Vanilloid Receptor TRPV1 by Calcineurin and cAMP-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.
[19] J. Lötsch,et al. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? , 2005, Trends in molecular medicine.
[20] S. Simon,et al. Chronic IL-1beta signaling potentiates voltage-dependent sodium currents in trigeminal nociceptive neurons. , 2006, Journal of neurophysiology.
[21] A. Imai,et al. Participation of the spinal TRPV1 receptors in formalin‐evoked pain transduction: a study using a selective TRPV1 antagonist, iodo‐resiniferatoxin , 2006, The Journal of pharmacy and pharmacology.
[22] S. Cruwys,et al. Sensory denervation with capsaicin attenuates inflammation and nociception in arthritic rats , 1995, Neuroscience Letters.
[23] D. Julius,et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.
[24] R. Latorre,et al. ThermoTRP channels as modular proteins with allosteric gating. , 2007, Cell calcium.
[25] A. Szallasi,et al. Biochemical pharmacology of the vanilloid receptor TRPV1 , 2004 .
[26] Vladimir A. Pavlyukovets,et al. Alpha-substituted N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists. , 2007, Bioorganic & medicinal chemistry.
[27] P. Ševčík,et al. Pain Research Update from a Genetic Point of View , 2005, Pain practice : the official journal of World Institute of Pain.
[28] A. Dubin,et al. Pharmacology and Antitussive Efficacy of 4-(3-Trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic Acid (5-Trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a Transient Receptor Potential Vanilloid 1 Antagonist in Guinea Pigs , 2007, Journal of Pharmacology and Experimental Therapeutics.
[29] P. McNaughton,et al. Proinflammatory Mediators Modulate the Heat-Activated Ion Channel TRPV1 via the Scaffolding Protein AKAP79/150 , 2008, Neuron.
[30] L. Vyklický,et al. Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites , 2005, Molecular and Cellular Neuroscience.
[31] P. Blumberg,et al. Antinociceptive Pharmacology of N-(4-Chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl) Thiourea, a High-Affinity Competitive Antagonist of the Transient Receptor Potential Vanilloid 1 Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.
[32] K. Bölcskei,et al. Pharmacological characterization of the TRPV1 receptor antagonist JYL1421 (SC0030) in vitro and in vivo in the rat. , 2005, European journal of pharmacology.
[33] Y. Ikemi,et al. Potentiation of transient receptor potential V1 functions by the activation of metabotropic 5‐HT receptors in rat primary sensory neurons , 2006, The Journal of physiology.
[34] Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. , 2006, Bioorganic & medicinal chemistry letters.
[35] H. Bluethmann,et al. Endogenous Tumor Necrosis Factor α (TNFα) Requires TNF Receptor Type 2 to Generate Heat Hyperalgesia in a Mouse Cancer Model , 2008, The Journal of Neuroscience.
[36] P. Moos,et al. Transient Receptor Potential Vanilloid 1 Agonists Cause Endoplasmic Reticulum Stress and Cell Death in Human Lung Cells , 2007, Journal of Pharmacology and Experimental Therapeutics.
[37] L. Stanciu,et al. Structure of TRPV1 channel revealed by electron cryomicroscopy , 2008, Proceedings of the National Academy of Sciences.
[38] P. McIntyre,et al. The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.
[39] L. Dekker,et al. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. , 1999, Neuron.
[40] U. Oh,et al. Histamine-induced Ca2+ influx via the PLA2/lipoxygenase/TRPV1 pathway in rat sensory neurons , 2004, Neuroscience Letters.
[41] A. Szallasi,et al. Capsaicin (TRPV1 Agonist) Therapy for Pain Relief: Farewell or Revival? , 2008, The Clinical journal of pain.
[42] J. Treanor,et al. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. , 2007, Journal of medicinal chemistry.
[43] S. McMahon,et al. Increasingly Irritable and Close to Tears: TRPA1 in Inflammatory Pain , 2006, Cell.
[44] J. Louis,et al. Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.
[45] T. Hökfelt,et al. Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic vanilloid treatment , 1995, Brain Research.
[46] Mark J. Rose,et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans , 2008, PAIN.
[47] M. Tominaga,et al. Direct Phosphorylation of Capsaicin Receptor VR1 by Protein Kinase Cε and Identification of Two Target Serine Residues* , 2002, The Journal of Biological Chemistry.
[48] A. Szallasi,et al. TRP channels and pain. , 2009, Current pharmaceutical design.
[49] D. Julius,et al. A Modular PIP2 Binding Site as a Determinant of Capsaicin Receptor Sensitivity , 2003, Science.
[50] W. Maixner,et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. , 2005, Human molecular genetics.
[51] S. Vanner,et al. Protease‐activated receptor 2 sensitizes TRPV1 by protein kinase Cɛ‐ and A‐dependent mechanisms in rats and mice , 2006 .
[52] Xinzhong Dong,et al. Pirt, a Phosphoinositide-Binding Protein, Functions as a Regulatory Subunit of TRPV1 , 2008, Cell.
[53] Jim A. Wright,et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.
[54] M. Dubé,et al. Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.
[55] R A Dionne,et al. Genetic predictors for acute experimental cold and heat pain sensitivity in humans , 2006, Journal of Medical Genetics.
[56] T. Neelands,et al. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia. , 2008, European journal of pharmacology.
[57] David Goldman,et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament , 2004, Pain.
[58] A. Dubin,et al. N-isoquinolin-5-yl-N'-aralkyl-urea and -amide antagonists of human vanilloid receptor 1. , 2004, Bioorganic & medicinal chemistry letters.
[59] P. McIntyre,et al. Cloning and functional characterization of the guinea pig vanilloid receptor 1 , 2002, Neuropharmacology.
[60] David Julius,et al. Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers , 2002, Cell.
[61] M. Caterina,et al. 5-Iodoresiniferatoxin Evokes Hypothermia in Mice and Is a Partial Transient Receptor Potential Vanilloid 1 Agonist in Vitro , 2005, Journal of Pharmacology and Experimental Therapeutics.
[62] A. Szallasi,et al. Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists , 2008 .
[63] R. Elde,et al. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites , 1999, The European journal of neuroscience.
[64] C. Foged,et al. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. , 2001, Molecular pharmacology.
[65] J. Treanor,et al. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles. , 2006, Journal of medicinal chemistry.
[66] J. Puzas,et al. Spinal interleukin-1beta in a mouse model of arthritis and joint pain. , 2008, Arthritis and rheumatism.
[67] S. Hwang,et al. Phosphorylation of Vanilloid Receptor 1 by Ca2+/Calmodulin-dependent Kinase II Regulates Its Vanilloid Binding* , 2004, Journal of Biological Chemistry.
[68] N. Chen,et al. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. , 2007, Journal of medicinal chemistry.
[69] S. Teague,et al. Functional Properties of the High-Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist (4-Hydroxy-5-iodo-3-methoxyphenylacetate ester) Iodo-Resiniferatoxin , 2002, Journal of Pharmacology and Experimental Therapeutics.
[70] B. Chizh,et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans , 2007, Pain.
[71] S. Nigam,et al. Biochemistry and pharmacology of endovanilloids. , 2007, Pharmacology & therapeutics.
[72] A. Imai,et al. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats , 2005, Neuropharmacology.
[73] J. Davies,et al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. , 1994, Journal of medicinal chemistry.
[74] R. Latorre,et al. A Hot-Sensing Cold Receptor: C-Terminal Domain Determines Thermosensation in Transient Receptor Potential Channels , 2006, The Journal of Neuroscience.
[75] S. Umland,et al. Cloning and pharmacological characterization of mouse TRPV1 , 2004, Neuroscience Letters.
[76] Qun Sun,et al. 4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists. , 2003, Bioorganic & medicinal chemistry letters.
[77] A. Miranda,et al. The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis , 2007, Neuroscience.
[78] J. Treanor,et al. The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation , 2007, The Journal of Neuroscience.
[79] J. Pomonis,et al. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain , 2003, Journal of Pharmacology and Experimental Therapeutics.
[80] C. Goso,et al. Competitive inhibition by capsazepine of [3H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat. , 1993, The Journal of pharmacology and experimental therapeutics.
[81] A. Ferrer-Montiel,et al. Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity* , 2004, Journal of Biological Chemistry.
[82] C. Créminon,et al. Neurogenic responses mediated by vanilloid receptor‐1 (TRPV1) are blocked by the high affinity antagonist, iodo‐resiniferatoxin , 2003, British journal of pharmacology.
[83] A. Gomtsyan,et al. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. , 2005, Journal of medicinal chemistry.
[84] L. Dekker,et al. Specific Involvement of PKC-ε in Sensitization of the Neuronal Response to Painful Heat , 1999, Neuron.
[85] Qun Sun,et al. Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists. , 2004, Bioorganic & medicinal chemistry letters.
[86] A. Basbaum,et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition , 2001, Nature.
[87] A. Gomtsyan,et al. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats , 2005, Journal of Pharmacology and Experimental Therapeutics.
[88] W. D. de Groat,et al. Neurokinin 2 receptor‐mediated activation of protein kinase C modulates capsaicin responses in DRG neurons from adult rats , 2008, The European journal of neuroscience.
[89] N. Chen,et al. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides. , 2007, Journal of medicinal chemistry.
[90] J. Treanor,et al. Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade , 2007, Journal of Pharmacology and Experimental Therapeutics.
[91] Attila Toth,et al. Molecular Determinants of Vanilloid Sensitivity in TRPV1* , 2004, Journal of Biological Chemistry.
[92] T. Oyama,et al. Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. , 2007, American journal of physiology. Renal physiology.
[93] L. Langeberg,et al. Coordination of Three Signaling Enzymes by AKAP79, a Mammalian Scaffold Protein , 1996, Science.
[94] P. McNaughton,et al. NGF rapidly increases membrane expression of TRPV1 heat‐gated ion channels , 2005, The EMBO journal.
[95] N. Chen,et al. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. , 2005, Journal of medicinal chemistry.
[96] Mark T. Kershaw,et al. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution. , 2008, Bioorganic & medicinal chemistry letters.
[97] W. Chambers,et al. Clinical Pain Management—Practice and Procedures , 2009 .
[98] I. Vetter,et al. The μ opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway , 2006, Molecular pain.
[99] C. Belmonte,et al. A Role of the Transient Receptor Potential Domain of Vanilloid Receptor I in Channel Gating , 2007, The Journal of Neuroscience.
[100] J. Chandrasekhar,et al. From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. , 2006, Bioorganic & medicinal chemistry letters.
[101] J. Lötsch,et al. Genetic mutations that prevent pain: implications for future pain medication. , 2008, Pharmacogenomics.
[102] Michael W. Salter,et al. TRPV1+ Sensory Neurons Control β Cell Stress and Islet Inflammation in Autoimmune Diabetes , 2006, Cell.
[103] A. Gomtsyan,et al. (R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo , 2008, Journal of Pharmacology and Experimental Therapeutics.
[104] P. Blumberg,et al. Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population. , 2004, Molecular pharmacology.
[105] Qun Sun,et al. N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties , 2003, Journal of Pharmacology and Experimental Therapeutics.
[106] A. Minassi,et al. The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. , 2005, Journal of medicinal chemistry.
[107] Z. Szallasi,et al. Resiniferatoxin: an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons. , 1990, The Journal of pharmacology and experimental therapeutics.
[108] A. Stein,et al. Phosphoinositide 3-Kinase Binds to TRPV1 and Mediates NGF-stimulated TRPV1 Trafficking to the Plasma Membrane , 2006, The Journal of general physiology.
[109] G. Fernández-Ballester,et al. Identification of a Tetramerization Domain in the C Terminus of the Vanilloid Receptor , 2004, The Journal of Neuroscience.
[110] D. Clapham,et al. Camphor Activates and Strongly Desensitizes the Transient Receptor Potential Vanilloid Subtype 1 Channel in a Vanilloid-Independent Mechanism , 2005, The Journal of Neuroscience.
[111] R. Raffa. Mechanism of action of analgesics used to treat osteoarthritis pain. , 2003, Rheumatic diseases clinics of North America.
[112] H P Rang,et al. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin , 1992, British journal of pharmacology.
[113] L. Langeberg,et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. , 1995, Science.
[114] C. Davies,et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist , 2004, Neuropharmacology.
[115] N. Gavva. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. , 2008, Trends in pharmacological sciences.
[116] R. Jostock,et al. Characterization of the mouse cold‐menthol receptor TRPM8 and vanilloid receptor type‐1 VR1 using a fluorometric imaging plate reader (FLIPR) assay , 2004, British journal of pharmacology.
[117] Yun Wang,et al. Interaction between protein kinase Cmu and the vanilloid receptor type 1. , 2004, The Journal of biological chemistry.
[118] A. Akopian,et al. A-kinase anchoring protein mediates TRPV1 thermal hyperalgesia through PKA phosphorylation of TRPV1 , 2008, PAIN.
[119] Jiyoun Lee,et al. High affinity antagonists of the vanilloid receptor. , 2002, Molecular pharmacology.
[120] G. Appendino,et al. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists , 2003, British journal of pharmacology.
[121] P. Chakrabarti,et al. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. , 2008, Journal of medicinal chemistry.
[122] D. J. Brasier,et al. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1) , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[123] A. Gomtsyan,et al. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel and Selective Transient Receptor Potential Type V1 Receptor Antagonist, Blocks Channel Activation by Vanilloids, Heat, and Acid , 2005, Journal of Pharmacology and Experimental Therapeutics.
[124] J. Treanor,et al. dioxin-6-yl ) acrylamide ] , a Novel Vanilloid Receptor 1 ( TRPV 1 ) Antagonist with Antihyperalgesic Properties , 2005 .
[125] C. Kamei,et al. Studies on somnolence in the daytime caused by drugs used for neuropathic pain. , 2008, Journal of pharmacological sciences.
[126] A. Szallasi,et al. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. , 2004, European journal of biochemistry.
[127] J. Treanor,et al. A Polyclonal Antibody to the Prepore Loop of Transient Receptor Potential Vanilloid Type 1 Blocks Channel Activation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[128] S. Topp,et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1 , 2000, Pain.